Fatty acid-like Pt(iv) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36
The fatty acid-like Pt(iv) prodrugs act as a “Trojan horse” to exploit upregulated CD36 receptors to facilitate their entry to ovarian cancer cells.
The fatty acid-like Pt(iv) prodrugs act as a “Trojan horse” to exploit upregulated CD36 receptors to facilitate their entry to ovarian cancer cells.